ID
45637
Beschrijving
Principal Investigator: Hernan A. Lorenzi, PhD, The J. Craig Venter Insititute, Rockville, MD, USA MeSH: Malaria,Malaria, Falciparum,Malaria Vaccines,Transcriptome,Gene Expression Profiling https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001346 Description: Experimental exposure to malaria parasites can lead to development of protective immunity, providing a foothold for the development of a malaria vaccine. The goal of this study is to investigate immune transcriptional profiles associated with malaria protective immune responses induced by experimental Chemo-Prophylaxis and Sporozoites (CPS) immunization of P. *falciparum*-naive human volunteers. Samples for this study were obtained from a CPS-immunization study conducted in 2011 (ClinicalTrials.gov Identifier: NCT01218893), where healthy volunteers received CPS-immunization with bites from different numbers of P. *falciparum*-infected mosquitoes (three times 15 (n=5), 10 (n=9) or 5 (n=10)). Five control subjects received uninfected mosquito bites under chloroquine prophylaxis. Fifteen weeks after discontinuation of chloroquine prophylaxis, all volunteers were challenged by exposure to infected mosquito bites. Study Design: A maximum of 30 volunteers were divided into four groups. All volunteers received weekly chloroquine prophylaxis for a period of 13 weeks (91 days). During these 13 weeks, on days 8, 36 and 64 they were exposed to the bites of 15 mosquitoes. Group 1 (n=5, positive control) received three CPS immunizations by 15 mosquitoes infected with P. falciparum sporozoites. Group 2 (n=10) received three times 10 bites from infected mosquitoes and 5 bites from uninfected mosquitoes. Group 3 (n=10) received three times 5 bites from infected mosquitoes and 10 bites from uninfected mosquitoes. Group 4 (n=5), the negative control, received three placebo immunizations with 15 bites of uninfected mosquitoes. Fifteen weeks after discontinuation of chloroquine prophylaxis, all 30 volunteers were challenged at day 196 by the bites of 5 infectious mosquitoes and followed for 21 days. All subjects were treated with chloroquine 21 days after challenge or whenever they had a positive thick smear during that period.
Link
Trefwoorden
Versies (1)
- 11-03-23 11-03-23 - Chiara Middel
Houder van rechten
Hernan A. Lorenzi, PhD, The J. Craig Venter Insititute, Rockville, MD, USA
Geüploaded op
11 maart 2023
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs001346 Human Gene Expression Patterns Associated with Experimental P. falciparum Infection
Subject ID and sex of participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, source subject ID, vaccination group, and consent group of participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use of samples obtained from participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
- Subject ID and sex of participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
- Sample ID, analyte type, body site where sample was obtained, clinical outcome, experimental stage, histological type of sample, tumor status of sample, sequence center, and time point of sample collection of participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
Similar models
Subject ID and sex of participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, source subject ID, vaccination group, and consent group of participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use of samples obtained from participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
- Subject ID and sex of participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.
- Sample ID, analyte type, body site where sample was obtained, clinical outcome, experimental stage, histological type of sample, tumor status of sample, sequence center, and time point of sample collection of participants involved in the "Human Gene Expression Patterns Associated with Experimental P. falciparum Infection" project.